[email protected] +1 646 480 7505 (U.S.) | +44 203 318 2846 (U.K.)

TABLE OF CONTENTS

1          Introduction

1.1       Market Definition

1.2       Market Scope

2          Research Methodology

2.1       Primary Research

2.2       Research Methodology

2.3       Assumptions & Exclusions

2.4       Secondary Data Sources

3          Market Overview

3.1       Report Segmentation & Scope

3.2       Value Chain Analysis: Anthrax Treatment Market

3.3       Key Market Trends

3.3.1    Drivers

3.3.2    Restraints

3.3.3    Opportunities

3.4       Porter’s Five Forces Analysis

3.4.1    Bargaining Power of Suppliers

3.4.2    Bargaining Power of Buyers

3.4.3    Threat of Substitution

3.4.4    Threat of New Entrants

3.4.5    Competitive Rivalry

3.5       Market Share Analysis

4          Route of Transmission Overview

4.1       Introduction

4.1.1    Market Size & Forecast (Value)

4.2       Cutaneous Anthrax

4.2.1    Market Size & Forecast (Value)

4.3       Inhalation Anthrax

4.3.1    Market Size & Forecast (Value)

4.4       Gastrointestinal Anthrax

4.4.1    Market Size & Forecast (Value)

4.5       Injection Anthrax

4.5.1    Market Size & Forecast (Value)

5          Drug Class Overview

5.1       Introduction

5.1.1    Market Size & Forecast (Value)

5.2       Antibiotics

5.2.1    Market Size & Forecast (Value)

5.3       Immuno Globulins

5.3.1    Market Size & Forecast (Value)

5.4       Others

5.4.1    Market Size & Forecast (Value)

6          End – use Overview

6.1       Introduction

6.1.1    Market Size & Forecast (Value)

6.2       Hospitals and clinics

6.2.1    Market Size & Forecast (Value)

6.3       Ambulatory surgery centers

6.3.1    Market Size & Forecast (Value)

6.4       Government agencies

6.4.1    Market Size & Forecast (Value)

6.5       Others

6.5.1    Market Size & Forecast (Value)

7          Regional Overview

7.1       Introduction

7.1.1    Market Size & Forecast (Value)

7.2       America

7.2.1    North America

7.2.1.1 U.S.

7.2.1.1.1          By Route of Transmission

7.2.1.1.2          Drug Class

7.2.1.2 Canada

7.2.1.2.1          By Route of Transmission

7.2.1.2.2          By Drug Class

7.2.1.3 Mexico

7.2.1.3.1          By Route of Transmission

7.2.1.3.2          By Drug Class

7.2.1.4 Latin America

7.2.1.4.1          By Route of Transmission

7.2.1.4.2          By Drug Class

7.3       Europe

7.3.1    Market Size & Forecast (Value)

7.3.2    Germany

7.3.2.1 By Route of Transmission

7.3.2.2 By Drug Class

7.3.3    France

7.3.3.1 By Route of Transmission

7.3.3.2 By Drug Class

7.3.4    U.K.

7.3.4.1 By Route of Transmission

7.3.4.2 By Drug Class

7.3.5    Italy

7.3.5.1 By Route of Transmission

7.3.5.2 By Drug Class

7.3.6    Spain

7.3.6.1 By Route of Transmission

7.3.6.2 By Drug Class

7.3.7    Rest of Europe

7.3.7.1 By Route of Transmission

7.3.7.2 By Drug Class

7.4       Asia Pacific

7.4.1    Market Size & Forecast (Value)

7.4.2    Japan

7.4.2.1 By Route of Transmission

7.4.2.2 By Drug Class

7.4.3    China

7.4.3.1 By Route of Transmission

7.4.3.2 By Drug Class

7.4.4    Australia

7.4.4.1 By Route of Transmission

7.4.4.2 By Drug Class

7.4.5    India

7.4.5.1 By Route of Transmission

7.4.5.2 By Drug Class

7.4.6    South Korea

7.4.6.1 By Route of Transmission

7.4.6.2 By Drug Class

7.4.7    Rest of Asia-Pacific

7.4.7.1 By Route of Transmission

7.4.7.2 By Drug Class

7.5       Middle East & Africa

7.5.1    Market Size & Forecast (Value)

7.5.2    Saudi Arabia

7.5.2.1 By Route of Transmission

7.5.2.2 By Drug Class

7.5.3    South Africa

7.5.3.1 By Route of Transmission

7.5.3.2 By Drug Class

7.5.4    Kuwait

7.5.4.1 By Route of Transmission

7.5.4.2 By Drug Class

7.5.5    Rest of Middle East & Africa

7.5.5.1 By Route of Transmission

7.5.5.2 By Drug Class

8          Company Profile

8.1       GlaxoSmithKline Pharmaceuticals Ltd.

8.1.1    Company Overview

8.1.2    Financial Performance

8.1.3    Recent Developments

8.1.4    Product Portfolio

8.2       Elusys Therapeutics Inc.

8.2.1    Company Overview

8.2.2    Financial Performance

8.2.3    Recent Developments

8.2.4    Product Portfolio

8.3       Emergent BioSolutions, Inc.

8.3.1    Company Overview

8.3.2    Financial Performance

8.3.3    Recent Developments

8.3.4    Product Portfolio

8.4       Altimune, Inc.

8.4.1    Company Overview

8.4.2    Financial Performance

8.4.3    Recent Developments

8.4.4    Product Portfolio

8.5       Teva Pharmaceutical Industries Ltd.

8.5.1    Company Overview

8.5.2    Financial Performance

8.5.3    Recent Developments

8.5.4    Product Portfolio

8.6       Novartis AG

8.6.1    Company Overview

8.6.2    Financial Performance

8.6.3    Recent Developments

8.6.4    Product Portfolio

8.7       Bayer AG

8.7.1    Company Overview

8.7.2    Financial Performance

8.7.3    Recent Developments

8.7.4    Product Portfolio



Request For Free Sample
Choose license Type

Buy Chapters or Sections

Avail customized purchase option to meet your exact research needs:

1)Buy sections of the report
2)Buy country level report
3)Request for historical data

Request a Free Sample   Special Pricing
Related Reports